A Phase 4 interventional study of Panax Notoginseng Saponins in Hematoma Absorption and Neurological Function Recovery, sponsored by The First People's Hospital of Jingzhou. Completed. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-12-21.
Sponsored by The First People's Hospital of Jingzhou · Phase 4, Interventional, and Treatment
The purpose of this study is to determine whether panax notoginseng saponins are effective in the treatment of Hypertensive Intracerebral Hemorrhage Patients.
Patients with HICH were randomly assigned to receive either PNS integrated with conventional therapy. Patients were treated with conventional therapy for 3 days, then plus PNS for 14 days. Patients in the control group received conventional therapy for 17days. Hematoma volume measured by CT scanning, National Institutes of Health Stroke Scale (NIHSS) scores, Barthel index (BI), all the three were used to evaluate the therapeutic effect for both groups after two weeks of intervention.
25 studies on the registry are indexed under Intracranial Hemorrhage, Hypertensive; 8 are open to participants now.
This study's enrollment of 90 is below the median of 306 across 19 interventional studies indexed under Intracranial Hemorrhage, Hypertensive.
Browse Intracranial Hemorrhage, Hypertensive studies →The First People's Hospital of Jingzhou is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients in the control group received conventional therapy for 17 days.conventional therapy consists of: (1) dehydration therapy by 20%mannitol (Tianjin Bane Medical Drugs Ltd., Co., China.) with the dosage from 125 to 250 ml every 8 h for 7 days depending on their clinically presumed intracranial pressure, (2) therapy to deal with complications including glucose-lowering treatment for hyperglycemia, antihypertensive treatment for hypertension, anti-inflammatory treatment for infection, acid inhibitor for peptic ulcer, and (3) supportive therapy, such as physical cooling, nutritional support, fluid, and electrolyte balance, which was provided as needed.
Patients in the intervention group received the same conventional therapy as in the control group for 3 days, brain CT was re-scanned at the 4th day, and was then given conventional therapy plus XUESAITONG Injection,which was mainly composed of Panax notoginseng saponins for 14 days from the 4th day.
Drug: Panax Notoginseng Saponins
Panax Notoginseng Saponins integrated with conventional therapy
Also known as: XUESAITONG Injection
Hematoma volume
Time frame: within the 14 days after two weeks of intervention
National Institutes of Health Stroke Scale (NIHSS) scores
were measured for stroke severity
Time frame: within the 14 days after two weeks of intervention
Barthel index
were measured for quality of life
Time frame: within the 14 days after two weeks of intervention
adverse events
such as rash, allergic shock
Time frame: 14 days
No study locations are listed for this record.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intracranial Hemorrhage, Hypertensive→
The First People's Hospital of Jingzhou